– USA, CA – Bolt Biotherapeutics (Nasdaq: BOLT) today announced the appointments of Brian O’Callaghan and Frank Lee to its Board of Directors.
The company also announced that Board member Dr. Jim Healy take the role of Lead Independent Director and that Dr. Peter Moldt is stepping down from the Board of Directors.
“Brian is a strategic leader with deep biotechnology and pharmaceutical experience across many therapeutics areas, leading new medicines from concept to commercialization. His leadership will prove invaluable as we advance our immuno-oncology pipeline. Frank brings experience shaping treatment paradigms for HER2 breast cancer patients from his time at Genentech and has a proven track record of commercial leadership in building innovative product strategies. We are eager to benefit from his knowledge as we make patient-focused decisions to expand our pipeline,” said CEO, Dr. Randall Schatzman.
He added: “Bolt Biotherapeutics has had a transformational year, from our February IPO to our steady progress in the BDC-1001 dose-escalation trial and establishment of collaborations with Genmab, Innovent Biologics, and Bristol Myers Squibb, all while advancing our novel pipeline and demonstrating our leadership in the immuno-oncology space. Dr. Moldt has been a tremendous contributor to Bolt’s successes as a private company over the last several years and on behalf of the whole Board of Directors, I would like to thank him for his hard work and dedication.”
About Brian O’Callaghan
Mr. O’Callaghan has 30 years of experience in biotechnology, pharmaceutical, and clinical research organizations, holding senior management and board roles at public and private companies in Europe and the U.S. He currently serves as CEO at ObsEva SA (Nasdaq: OBSV), a clinical-stage pharmaceutical company developing novel therapies to improve women’s health. Mr. O’Callaghan also serves on the board of several privately-held biotechnology companies, including Indaptus Therapeutics, Aquavit Therapeutics, and Biocom Purchasing Group. Earlier, he held CEO positions at Petra Pharma, Acucela, Sangart, and NPS BioPartners, as well as senior management positions at Pfizer, Merck Serono, Novartis, Covance, and NPS Pharmaceuticals.
“Bolt has formed a robust pipeline of immune-stimulating, myeloid-engaging therapeutics to offer long-term tumor remissions for patients. The uniqueness of the Boltbody™ Immune-stimulating Antibody Conjugate approach is intriguing, and I look forward to sharing my experience with the Bolt team as they advance pipeline programs through clinical development,” said Mr. O’Callaghan.
Mr. O’Callaghan earned an M.B.A. from the Henley Business School at the University of Reading and a diploma from the Marketing Institute of Ireland.
About Frank Lee
Mr. Lee has more than 25 years of experience in product development and commercial leadership across a wide range of therapeutic areas within the biotech and pharmaceutical industries. He currently serves as President and CEO of Forma Therapeutics (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers. Before joining Forma, Mr. Lee spent 13 years at Genentech, where he was most recently SVP of global product strategy. Previously, as VP of Genentech’s HER2/breast cancer franchise, he was responsible for U.S. P&L for Herceptin, Perjeta, and Kadcyla, driving revenues over $4 billion and launching the first HER2 neoadjuvant indication for early HER2 breast cancer patients. Previously, as VP of oral oncolytics at Genentech, Mr. Lee held P&L responsibility for Tarceva, Zelboraf, Erivedge, and Xeloda, advancing personalized medicine for cancer patients with EGFR+ NSCLC and BRAF+ melanoma, and establishing a new treatment option for patients with advanced basal cell carcinoma. Before joining Genentech, Mr. Lee spent approximately 13 years at Novartis, Janssen, and Eli Lilly.
“Bolt is pioneering a new category of immunotherapies based on the Boltbody ISAC platform and is well poised to make a transformative impact on the lives of patients,” said Mr. Lee. “I am excited to help the Bolt Biotherapeutics drive patient-focused decisions that could advance and grow the company’s pipeline of product candidates.”
Mr. Lee earned a B.E. in Chemical Engineering from Vanderbilt University and an M.B.A. from the Wharton Graduate School of Business at the University of Pennsylvania.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems Bolt’s proprietary Boltbody Immune-stimulating Antibody Conjugate approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells. This leads to the conversion of immunologically “cold” tumors to “hot” tumors. Bolt’s lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of Bolt’s proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. Bolt is also advancing additional Boltbody ISAC product candidates targeting CEA and PD-L1.
For more information: https://www.boltbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
